[1] 陈谦明. 口腔黏膜病学[M]. 北京: 人民卫生出版社, 2012:64-67. Chen QM. Oral mucosal diseases[M]. Beijig: People’s Me-dical Publishing House, 2012:64-67. [2] Freeman GJ, Wherry EJ, Ahmed R, et al. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand bloc-kade[J]. J Exp Med, 2006, 203(10):2223-2227. [3] Okazaki T, Maeda A, Nishimura H, et al. PD-1 immunorecep-tor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine[J]. Proceed Natl Acad Sci, 2001, 98(24):13866-13871. [4] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26:677-704. [5] 贺兰湘, 张桂梅, 贺宇飞, 等. sPD-1封闭PD-L促进抗肿瘤免疫的机制研究[J]. 中华微生物学和免疫学杂志, 2006, 26(5):463-467. He LX, Zhang GM, He YF, et al. Mechanism of antitumor immunity of PD-L blockade with sPD-1[J]. Chin J Micro-biol Immunol, 2006, 26(5):463-467. [6] Shi B, Du X, Wang Q, et al. Increased PD-1 on CD4 + CD28 - T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases[J]. Metabolism, 2013, 62(6):778-785. [7] 季枚. PD-L1在非小细胞肺癌中表达的生物学作用及临床意义[D]. 苏州: 苏州大学, 2016. Ji M. Clinical significance of PD-L1 expression in human non- small-cell lung cancer and the study of its biological function[D]. Suzhou: Suzhou University, 2016. [8] Momin S, Flores S, Angel BB, et al. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes[J]. Diabetes Res Clin Pract, 2009, 83(3):289-294. [9] 张华昌, 范小平, 向学熔, 等. 复发性阿弗他溃疡患者的T淋巴细胞免疫因素的研究[J]. 重庆医学, 2010, 39(10):1239-1240. Zhang HC, Fan XP, Xiang XR, et al. Relationship between recurrent aphthous ulcer and immune factor of T lymphocyte[J]. Chongqing Med, 2010, 39(10):1239-1240. [10] Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function[J]. Im-munol Rev, 2009, 229(1):88-100. [11] Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance[J]. J Exper Med, 2006, 203(4):883-895. [12] Bhadra R, Gigley JP, Khan IA. PD-1-mediated attrition of polyfunctional memory CD8 + T cells in chronic toxoplasma infection[J]. J Infect Dis, 2012, 206(1):125-134. [13] Okazaki T, Wang J. PD-1/PD-L pathway and autoimmunity[J]. Autoimmunity, 2005, 38(5):353-357. [14] 赵瑾. 可溶性PD-L1分子对T淋巴细胞功能的影响及其机制[D]. 苏州: 苏州大学, 2015. Zhao J. Effect of soluble programmed death ligand 1 on regulating the function of T lymphocytes and its mechanism[D]. Suzhou: Suzhou University, 2015. [15] 王师, 罗龙龙, 吕明, 等. PD-1/PD-L1信号通路及其在肿瘤中的应用[J]. 国际药学研究杂志, 2015, 42(2):143-147. Wang S, Luo LL, Lü M, et al. PD-1/PD-L1 signaling path-way and its application in tumor[J]. J Int Pharm Res, 2015, 42(2):143-147. |